Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA.
Br J Haematol. 2024 Sep;205(3):767-769. doi: 10.1111/bjh.19676. Epub 2024 Jul 27.
Kaiser et al. offer management recommendations for transplant-eligible, high-risk multiple myeloma (HRMM), derived from recent trials exploring treatment intensification in the various phases of front-line therapy. The definition of HRMM continues to evolve with emergence of novel genomic insights and impact of modern therapies, underscoring the need to expand beyond traditional interphase fluorescence in situ hybridization cytogenetics and International Staging System staging for a precise risk assessment. Despite progress, ongoing challenges in treatment delivery and tolerability underscore the urgency for exploring novel approaches like T-cell redirecting bispecific antibodies and chimeric antigen receptor T-cell to enhance outcomes in this complex patient population. Commentary on: Kaiser et al. Diagnosis and initial treatment of transplant-eligible high-risk myeloma patients: A British Society for Haematology/UK Myeloma Society Good Practice Paper. Br J Haematol 2024; 205:833-839.
凯泽等人从探索一线治疗各个阶段治疗强化的近期试验中，为适合移植的高危多发性骨髓瘤（HRMM）提供了管理建议。随着新型基因组见解的出现和现代疗法的影响，HRMM 的定义不断演变，这凸显了需要超越传统的间期荧光原位杂交细胞遗传学和国际分期系统分期，以进行精确的风险评估。尽管取得了进展，但在治疗实施和耐受性方面持续存在的挑战，突显了探索新型方法（如 T 细胞重定向双特异性抗体和嵌合抗原受体 T 细胞）的紧迫性，以提高这一复杂患者群体的治疗效果。评论：凯泽等人。适合移植的高危骨髓瘤患者的诊断和初始治疗：英国血液学学会/英国骨髓瘤学会实践指南。英国血液学杂志 2024；205：833-839。
